Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Shares Purchased by Russell Investments Group Ltd.

Russell Investments Group Ltd. increased its holdings in Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) by 36.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 290,228 shares of the medical device company's stock after buying an additional 77,594 shares during the quarter. Russell Investments Group Ltd. owned about 0.44% of Tandem Diabetes Care worth $10,454,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. AlphaQuest LLC increased its holdings in shares of Tandem Diabetes Care by 138.7% during the 4th quarter. AlphaQuest LLC now owns 931 shares of the medical device company's stock valued at $34,000 after purchasing an additional 541 shares in the last quarter. Jones Financial Companies Lllp grew its position in shares of Tandem Diabetes Care by 195.8% during the 4th quarter. Jones Financial Companies Lllp now owns 1,130 shares of the medical device company's stock valued at $41,000 after acquiring an additional 748 shares during the period. Assetmark Inc. grew its holdings in Tandem Diabetes Care by 77.5% in the fourth quarter. Assetmark Inc. now owns 1,225 shares of the medical device company's stock valued at $44,000 after purchasing an additional 535 shares during the period. McIlrath & Eck LLC acquired a new stake in Tandem Diabetes Care in the 3rd quarter valued at $52,000. Finally, Smartleaf Asset Management LLC increased its holdings in Tandem Diabetes Care by 163.4% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,775 shares of the medical device company's stock worth $65,000 after acquiring an additional 1,101 shares in the last quarter.

Remove Ads

Analyst Ratings Changes

A number of research firms have recently commented on TNDM. Sanford C. Bernstein cut shares of Tandem Diabetes Care from an "outperform" rating to a "market perform" rating and cut their target price for the stock from $35.00 to $25.00 in a research note on Friday, February 28th. Canaccord Genuity Group reiterated a "buy" rating and issued a $63.00 price objective on shares of Tandem Diabetes Care in a report on Wednesday, February 26th. The Goldman Sachs Group reduced their price objective on Tandem Diabetes Care from $42.00 to $24.00 and set a "neutral" rating on the stock in a research report on Monday, March 3rd. Citigroup downgraded shares of Tandem Diabetes Care from a "buy" rating to a "neutral" rating and reduced their target price for the stock from $35.00 to $24.00 in a research note on Tuesday, March 4th. Finally, Wells Fargo & Company reissued an "equal weight" rating and set a $22.00 target price (down previously from $38.00) on shares of Tandem Diabetes Care in a research note on Monday, March 3rd. Nine investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $43.88.

Insider Buying and Selling

In other news, COO Jean-Claude Kyrillos bought 10,538 shares of the firm's stock in a transaction that occurred on Friday, March 7th. The stock was purchased at an average cost of $18.12 per share, with a total value of $190,948.56. Following the transaction, the chief operating officer now directly owns 10,538 shares in the company, valued at $190,948.56. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 2.20% of the stock is owned by company insiders.

Tandem Diabetes Care Stock Up 4.0 %

TNDM stock traded up $0.68 during midday trading on Tuesday, reaching $17.71. 1,241,623 shares of the company were exchanged, compared to its average volume of 1,501,528. The stock's 50-day simple moving average is $23.23 and its 200 day simple moving average is $30.64. Tandem Diabetes Care, Inc. has a 1-year low of $15.75 and a 1-year high of $53.69. The company has a debt-to-equity ratio of 1.29, a quick ratio of 2.32 and a current ratio of 2.90. The company has a market cap of $1.18 billion, a price-to-earnings ratio of -9.18 and a beta of 1.52.

Tandem Diabetes Care Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.